Načítá se...
Tumor immunity landscape in non-small cell lung cancer
Even with the great advances in immunotherapy in recent years, the response rate to immune checkpoint inhibitor therapy for non-small cell lung cancer is only about 20%. We aimed to identify new features that would better predict which patients can benefit from an immune checkpoint blocker. This stu...
Uloženo v:
| Vydáno v: | PeerJ |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
PeerJ Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5868477/ https://ncbi.nlm.nih.gov/pubmed/29593943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7717/peerj.4546 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|